Skip to content

Discontinued — last reported Q1 '26

Interest Expense at other companies

Opko Health logo
Opko HealthOPK
$10.94M-29.3%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$1.01M-5.2%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$4.37M+46.5%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$13.87M+2.5%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$8.06M+17.0%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$272M+33.3%

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%
Enterprise value$1.29B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's interest expense?
MoonLake Immunotherapeutics (MLTX) reported interest expense of $2.27M in Q1 2026.
How has MoonLake Immunotherapeutics's interest expense changed year-over-year?
MoonLake Immunotherapeutics's interest expense increased by 12505.6% year-over-year, from $18K to $2.27M.
What does interest expense mean?
Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.